Colleges
Biography
Kevin Talbot qualified in medicine (MB BS) with Distinction from the University of London and trained in Neurology in London and Oxford. He joined the laboratory of Professor Kay Davies in 1995 to work on the childhood motor neuron disorder spinal muscular atrophy, which has remained a major focus of his research ever since. From 1998-2001 he was Clinical Lecturer in Neurology and from 2001-2006 held an MRC Clinician Scientist Fellowship. He founded the Oxford MND clinic at the John Radcliffe Hospital, with a multidisciplinary team providing a clinical service for patients with motor neuron disease from all over the South of England. In 2010 he became Professor of Motor Neuron Biology.
Awards, Training and Qualifications
- MB BS University of London 1990
- DPhil University of Oxford 1998
- FRCP Royal College of Physicians, London 2006
Kevin Talbot
MB BS, DPhil, FRCP
Head of Department and Professor of Motor Neuron Biology
Research groups
Websites
-
Division of Clinical Neurology
Research Centre
-
Kavli Institute for Nanoscience Discovery
Research Centre
Research Summary
The main aim of my research is to identify targets for therapy in motor neuron diseases such as amyotrophic lateral sclerosis (ALS). In particular, we use laboratory models including motor neurons from induced pluripotent stem cells from patients to understand why motor neuron integrity fails in the presence of certain genetic mutations (eg; TDP-43 or C9orf72 in ALS). We also use these models to identify drug targets. Our work takes place in the context of a larger team of researchers in Oxford interested in translational research in neurodegenerative diseases, and we have many national and international collaborations. We are active members of the UK MND Research Institute.
DPHIL PROJECTS
Professor Talbot is not currently accepting new DPhil students.
Sources of Funding
- Motor Neuron Disease Association 2001-2026
- MND Scotland 2023-2026
- My Name'5 Doddie Foundation 2019-2026
- Alan Davidson Foundation 2022-2025
- NIHR 2022-2027
Recent publications
-
Elevated Cerebrospinal Fluid Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1 in Asymptomatic C9orf72 Hexanucleotide Repeat Expansion Carriers.
Dellar ER. et al, (2024), Ann Neurol
-
The Basis of Cognitive and Behavioral Dysfunction in Amyotrophic Lateral Sclerosis.
Bampton A. et al, (2024), Brain Behav, 14
-
Dynactin-1 mediates rescue of impaired axonal transport due to reduced mitochondrial bioenergetics in amyotrophic lateral sclerosis motor neurons
Dafinca R. et al, (2024), Brain Communications
-
Personalised penetrance estimation forC9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia
Douglas AGL. et al, (2024), BMJ Neurology Open, 6, e000792 - e000792
-
Cellular and axonal transport phenotypes due to the C9ORF72 HRE in iPSC motor and sensory neurons.
Scaber J. et al, (2024), Stem Cell Reports